INVESTORS

Investor Relations

Recent News
Feb 21, 2018

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Feb 6, 2018

- Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th - VANCOUVER, Feb. 6, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

Jan 29, 2018

- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston - VANCOUVER, Jan. 29, 2018 /CNW/...

View all news releases

Events and Webcasts
Tuesday, February 27, 2018
10:00am - 12:00pm EST

Event RSVP: http://events.constantcontact.com/register/event?llr=mlhnstzab&oeidk=a07ef2arrx7482b90e8

View all events and webcasts

Investor enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts